|
Rosetta Genomics, Ltd as well as the NYU Langone Health examination Center recently published a joint study called the “Pro-tumorigenic Effects of miR-31 Loss in Mesothelioma” that suggests that the take of miR-31 may be a viable therapeutic treatment to suppress tumors in mesothelioma patients. In the study, mesothelioma patients were found to lack miR-31, a microRNA recently found to suppress breast cancer metastases. Introduction of miR-31 to the mesothelioma patients in the study suppressed growth, migration as well as invasion of cancerous cells. In the expected, therapies involving miR-31 as well as other microRNAs may add years to the life of cancer patients by slowing the advance of the cancerous cells without damaging wholesome tissues. It is substantial to note that there is often a extended wait between scientific studies as well as marketable therapies approved by the Federal Food as well as Drug Administration for take on patients. For the filled story, go to Market Watch. |